These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26878738)

  • 1. Removal of Review and Reclassification Procedures for Biological Products Licensed Prior to July 1, 1972. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Feb; 81(29):7445-6. PubMed ID: 26878738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revocation of General Safety Test Regulations That Are Duplicative of Requirements in Biologics License Applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2015 Jul; 80(127):37971-4. PubMed ID: 26155602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological products; bacterial vaccines and toxoids; implementation of efficacy review. Final rule and final order.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Jan; 69(2):255-67. PubMed ID: 14968793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisions to the general safety requirements for biological products--FD. Direct final rule.
    Fed Regist; 1998 Apr; 63(75):19399-403. PubMed ID: 10178869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard Preparations, Limits of Potency, and Dating Period Limitations for Biological Products. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 May; 81(86):26687-92. PubMed ID: 27192727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conforming regulations regarding removal of section 507 of the Federal Food, Drug, and Cosmetic Act; confirmation of effective date. Food and Drug Administration, HHS. Direct final rule; confirmation of effective date.
    Fed Regist; 1999 May; 64(94):26657. PubMed ID: 10558515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Removal of Certain Time of Inspection and Duties of Inspector Regulations for Biological Products. Direct final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2018 Jan; 83(18):3586-9. PubMed ID: 29372981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmarketing safety reports for human drug and biological products; electronic submission requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2014 Jun; 79(111):33072-92. PubMed ID: 24922981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revocation of status of specific products; Group A streptococcus. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Dec; 70(231):72197-9. PubMed ID: 16323338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Content and format for labeling for human prescription drugs; amendment of effective date for certain biological products--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(15 pt 1):7271-3. PubMed ID: 10249526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ophthalmic drug products for over-the-counter human use; final monograph; technical amendment. Final rule; technical amendment.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Feb; 68(33):7919-21. PubMed ID: 12593411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revision to requirements for licensed Anti-Human Globulin and Blood Grouping Reagents. Food and Drug Administration, HHS. Direct final rule.
    Fed Regist; 2000 Dec; 65(239):77497-9. PubMed ID: 11503726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiperspirant drug products for over-the-counter human use; final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(110):34273-93. PubMed ID: 12795305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Food and Drug Administration regulations and licensure.
    Barker LF
    Fed Proc; 1975 May; 34(6):1522-4. PubMed ID: 1126452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional criteria and procedures for classifying over-the-counter drugs as generally recognized as safe and effective and not misbranded. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jan; 67(15):3060-76. PubMed ID: 11820251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidiarrheal drug products for over-the-counter human use; final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Apr; 68(74):18869-82. PubMed ID: 12701600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Removal of regulations regarding certification of drugs composed wholly or partly of insulin--FDA. Direct final rule.
    Fed Regist; 1998 May; 63(92):26694-9. PubMed ID: 10179341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.